Corporate ActionMay 28, 2026, 05:12 PM
Outlook Therapeutics to raise $5.0M via direct offering; amends warrants
AI Summary
Outlook Therapeutics, Inc. entered into a securities purchase agreement to sell 8,539,709 shares of common stock at $0.5855 per share in a registered direct offering, expecting gross proceeds of approximately $5.0 million. The company intends to use the net proceeds for working capital and general corporate purposes. Additionally, the company amended existing warrants held by the purchaser, GMS Ventures and Investments (affiliated with company directors), reducing the exercise price for 15,488,570 shares from a weighted average of $1.78 to $0.5855 per share.
Key Highlights
- Outlook Therapeutics to raise approximately $5.0 million in gross proceeds from a registered direct offering.
- The company will issue 8,539,709 shares of common stock at an offering price of $0.5855 per share.
- The registered direct offering is expected to close on or about May 29, 2026.
- Net proceeds from the offering will be used for working capital and general corporate purposes.
- The company amended warrants for 15,488,570 shares, reducing the exercise price from $1.78 to $0.5855 per share.
- The purchaser, GMS Ventures and Investments, is affiliated with Outlook Therapeutics' directors.
Price Impact
More from OTLK